These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 16621431)
1. Comprehensive management of diffuse malignant peritoneal mesothelioma. Sugarbaker PH; Yan TD; Stuart OA; Yoo D Eur J Surg Oncol; 2006 Aug; 32(6):686-91. PubMed ID: 16621431 [TBL] [Abstract][Full Text] [Related]
2. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159 [TBL] [Abstract][Full Text] [Related]
3. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335 [TBL] [Abstract][Full Text] [Related]
4. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. Deraco M; Casali P; Inglese MG; Baratti D; Pennacchioli E; Bertulli R; Kusamura S J Surg Oncol; 2003 Jul; 83(3):147-53. PubMed ID: 12827682 [TBL] [Abstract][Full Text] [Related]
5. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. Chua TC; Yan TD; Morris DL J Surg Oncol; 2009 Feb; 99(2):109-13. PubMed ID: 19016259 [TBL] [Abstract][Full Text] [Related]
7. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562 [TBL] [Abstract][Full Text] [Related]
8. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive cases. Yan TD; Edwards G; Alderman R; Marquardt CE; Sugarbaker PH Ann Surg Oncol; 2007 Feb; 14(2):515-25. PubMed ID: 17031722 [TBL] [Abstract][Full Text] [Related]
9. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience. Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401 [TBL] [Abstract][Full Text] [Related]
10. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. Feldman AL; Libutti SK; Pingpank JF; Bartlett DL; Beresnev TH; Mavroukakis SM; Steinberg SM; Liewehr DJ; Kleiner DE; Alexander HR J Clin Oncol; 2003 Dec; 21(24):4560-7. PubMed ID: 14673042 [TBL] [Abstract][Full Text] [Related]